Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The U.S. Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper bound of the two-sided 95% CI for major adverse CV events (MACE) of less than 1.80 preapproval and 1.30 postapproval. Over 25 large, prospective, randomized, controlled clinical trials involving nearly 195,000 subjects thus far have been completed or are ongoing in accordance with this guidance. The results of seven trials have been presented so far—three with dipeptidyl peptidase 4 inhibitors, one with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, and three with glucagon-like peptide 1 receptor agonists (GLP-1 RA). While all seven trials showed noninferiority in the rate of MACE with the use of these agents compared with placebo, three of them revealed CV benefits. Treatment with empagliflozin (an SGLT2 inhibitor) and treatment with liraglutide (a GLP-1 RA) both significantly reduced the risk of MACE, mortality from CV causes, and mortality from any cause when compared with placebo. Treatment with semaglutide, another GLP-1 RA, showed a significantly lower rate of MACE but not mortality from CV or any cause compared with placebo. In all of the trials, the effects of treatment on outcomes were out of proportion to the small differences in glycemic control levels, suggesting that the effects observed were likely unrelated to differences in the glucose-lowering efficacy. Overall, the results of these trials yield a favorable benefit-risk balance for these therapies in mitigating CV risk in patients with type 2 diabetes. More research is needed to elucidate the underlying mechanisms and confirm whether the CV benefits are a class effect or whether the benefits persist in patients without established CV disease or are evident even in patients without diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the hsCRP reduction observed with the GLP-1RA semaglutide suggests that it might exert anti-inflammatory effects.”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [38]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Primarily in response to the findings of possible increased CV risk with rosiglitazone (2), the U.”
BackgroundMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 7×
“Thus, there are legitimate arguments for including silent MIs in the overall adjudication ofMIs in CV outcome trials.”
MethodInfluentialEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Research works printed but not linked: 1
- Committee for Medicinal Products for Human Use, 2012, Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus
Cited by
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“The CV risk reduction (RR) observed using the GLP1RAs liraglutide and semaglutide in the LEADER and SUSTAIN-6 trials is proposed to be mediated through antiatherosclerotic mechanisms (6,7,9).”
MethodDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
“…questions about the potential clinical classes used for treatment of T2D, the GLP-1R agonists and SGLT-2 inhibitors, produce weight loss, effective reduction of A1c, a low incidence of hypoglycemia, and reductions in rates of major adverse cardiovascular events and cardiovascular death (75, 87).”
BackgroundDedov, I. I., Shestakova, M. V., Vikulova, O. K., Zheleznyakova, A. V., Isakov, M. A., Sazonova, D. V., & Mokrysheva, N. G. (2023) · Diabetes mellitus · doi:10.14341/dm13035 · Cited by 281
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., et al. (2019) · Diabetes mellitus · doi:10.14341/dm221s1 · Cited by 257
Dedov, I., Shestakova, M., Mayorov, A., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Beshlieva, D., et al. (2023) · Diabetes mellitus · doi:10.14341/dm13042 · Cited by 214
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Mokrysheva, N. G., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., et al. (2022) · Diabetes mellitus · doi:10.14341/dm12802 · Cited by 207
The myth of ‘stable’ coronary artery disease
Fox, K. A. A., Metra, M., Morais, J., & Atar, D. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0233-y · Cited by 189
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
O’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Hu, R., Xia, C., Butfiloski, E. J., & Clare-Salzler, M. J. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.06.003 · Cited by 110
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1423852 · Cited by 102
“tant to the CV hemodynamics, while noting the very modest differences in glucose measurements [17].”
BackgroundMosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“As inflammation is an important process in CV disease [1, 2] and GLP-1RAs are hypothesized to lower CV risk via attenuation of atherosclerosis [37, 38], the hsCRP reduction observed with the GLP-1RA semaglutide suggests that it might exert anti-inflammatory effects.”
BackgroundCardiovascular outcome trials of glucose-lowering medications: an update
Home, P. (2019) · Diabetologia · doi:10.1007/s00125-018-4801-1 · Cited by 82
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
Kaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Kitakata, H., Endo, J., Hashimoto, S., Mizuno, E., Moriyama, H., Shirakawa, K., Goto, S., Katsumata, Y., Fukuda, K., & Sano, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.090 · Cited by 61
Onoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 57
Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157917 · Cited by 51
Arroyave, F., Montaño, D., & Lizcano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228685 · Cited by 62
Dedov, I., Shestakova, M., Sukhareva, O., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Bessmertnaya, E., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm20255s · Cited by 60
Lahoti, S., Nashawi, M., Sheikh, O., Massop, D., Mir, M., & CHILTON, R. J. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000209 · Cited by 40
Díaz-Trastoy, O., Villar‐Taibo, R., Sifontes-Dubón, M., Mozo-Peñalver, H., Bernabéu, I., Cabezas-Agrícola, J. M., Muñoz-Leira, V., Peinó-García, R., Martís-Sueiro, A., López, J. M. G., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.012 · Cited by 37
Clegg, L. E., Heerspink, H. J. L., Penland, R. C., Tang, W., Boulton, D. W., Bachina, S., Fox, R. D., Fenici, P., Thuresson, M., Mentz, R. J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1871 · Cited by 33
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 32
Webb, J., Mount, J., von Arx, L., Rachman, J., Spanopoulos, D., Wood, R. P., Tritton, T., Massey, O., & IDRIS, I. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14580 · Cited by 24
“The inclusion criteria of CVOTs are often aimed at enriching the study population with patients with high CV risk in order to accrue sufficient events in a timely manner.(6,16) While this approach is efficient, and not inappropriate given the primary safety-related purpose”
BackgroundHurren, K. M., & Dunham, M. W. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494727 · Cited by 20
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 23
Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21
Kuo, S., Ye, W., Duong, J. J., & Herman, W. H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.040 · Cited by 22
Bułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., & Okopień, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7245 · Cited by 21
Drexel, H., Rosano, G. M. C., Lewis, B. S., Huber, K., Vonbank, A., Dopheide, J. F., MADER, A., Niessner, A., Savarese, G., Waßmann, S., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz029 · Cited by 20
Sinha, A., Puri, P., & Pati, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061154 · Cited by 14
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
The Bariatric-Metabolic Physician’s Role in Managing Clinically Severe Obesity
Matta-Coelho, C., Crane, J. D., Agius, R., & McGowan, B. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00435-z · Cited by 14
Chen, B., Tao, L., Tian, M., & Ji, Z. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.056 · Cited by 11
Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
Silva‐Cardoso, J., Sheikh, O., Nashawi, M., Pham, S. V., Gallegos, K. M., Dinkha, L. R., & CHILTON, R. J. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.13007 · Cited by 10
Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Sanada, J., Fushimi, Y., Katakami, N., Matsuoka, T., & Kaku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249444 · Cited by 9
“(2) SUSTAIN-6 trial [63,64]: This study included 3297 subjects with type 2 diabetes, randomly allocated to either the once-weekly semaglutide or the placebo and was followed up for 2 years.”
BackgroundPrevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications
Bassi, N. S., & Fonarow, G. C. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1050-3 · Cited by 8
Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1430446 · Cited by 6
“Several authors think that the effect of liraglutide is through an alteration of the factors leading to the progression of the atherosclerotic process or the processes leading to atherothrombotic events, but this remains unproven [13,19,20].”
BackgroundThuesen, A. C. B., & Vaag, A. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13238 · Cited by 5
“There is general consensus that glucose lowering per se is unlikely to explain the reduced mortality with GLP-1 agonists as well as with SGLT2 inhibitors.(71,72) The U-shaped relationship between HbA1c and mortality is vexing because it is counterintuitive to our definition of the disease.”
BackgroundCardiovascular benefits of metformin in T1DM
Snell‐Bergeon, J. K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.116 · Cited by 4
Ghouri, N., Javed, H., & Sattar, N. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399817666201228120725 · Cited by 6
“If we start with Asian specific data in EMPA-REG trial [66], empagliflozin reduced the occurrence of the primary outcome by 32% and CV death by 56%, HR: 0.”
Салухов, В. В. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-4-44-51 · Cited by 6
Tantawy, D., Rabih, M. R. M., Mohamed, R. S., Ali, M. K., Aldeen, R. S. A. M. S., Abdelkarim, A. O. A., & Mohamedzain, T. G. A. (2025) · Cureus · doi:10.7759/cureus.96218 · Cited by 4
“…cardiovascular outcome trials (CVOTs) such as EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), and LEADER (liraglutide) demonstrated reductions in major adverse cardiovascular events (MACE), establishing these therapies as cornerstones of cardiometabolic risk mitigation in T2DM [7].”
Inibidores da SGLT2 e suas influências no sistema cardiovascular: uma revisão sistemática
Silva, G. A., Carreira, R. G., Garcia, W. F., & Filho, A. E. C. (2020) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e3325.2020 · Cited by 9
Le seuil du « p » statistique à 0,05 est-il fiable ou non ? Telle est la question
Monnier, L., Colette, C., & Halimi, S. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30177-9 · Cited by 5
Liraglutide and systolic blood pressure
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13443 · Cited by 2
Kaul, S. (2017) · Diabetes Care · doi:10.2337/dci17-0044 · Cited by 2
“Finally, I would like to thank the author for pointing out the typographical error with regard to hospitalization for heart failure results summarized in Table 3 (1).”
BackgroundSelf-citationFreichel, M., & Mengel, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_14 · Cited by 1
Feldman-Billard, S. (2017) · Diabetes Care · doi:10.2337/dc17-1527 · Cited by 1
Gong, T., & HALL, S. A. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0574-9
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.313485
“The main criticism raised by Tampaki et al on EMPA-REG OUTCOME concerns the quotation of cardiovascular events and deaths, a remark raised by the Food and Drug Administration and already discussed.(2) Although cardiovascular death was not explicitly part of the confirmatory testing hierarchy, the reduction seems to be…”
BackgroundHanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1076-0738 · Cited by 1
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Freichel, M., & Mengel, K. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_14
Mosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“Accumulating evidence suggests that the favorable cardiovascular outcomes observed with GLP-1RAs, may be partially mediated through anti-inflammatory mechanisms that extend beyond glucose-lowering alone [33, 63, 171].”
Metadata
- Authors
- Kaul, S.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Kaul, Sanjay
- ORCID
- Kaul, Sanjay
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-06-13
- Volume
- 40
- Issue
- 7
- Pages
- 821-831
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2711994541
- Cited by
- 62
- References
- 29
- Citations by year
- 2026: 2 · 2025: 4 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 11 · 2018: 18 · 2017: 6
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-03-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, cardiovascular risk, major adverse cardiovascular events, empagliflozin, liraglutide, semaglutide, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, EMPA-REG OUTCOME, LEADER trial, SUSTAIN 6 trial, benefit-risk balance, cardiovascular mortality
- MeSH terms
- Liraglutide, Semaglutide, Animals, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides, Humans, Hypoglycemic Agents, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.